CN109562179A - N,n-双-2-巯基乙基间苯二甲酰胺的新用途 - Google Patents

N,n-双-2-巯基乙基间苯二甲酰胺的新用途 Download PDF

Info

Publication number
CN109562179A
CN109562179A CN201780046065.1A CN201780046065A CN109562179A CN 109562179 A CN109562179 A CN 109562179A CN 201780046065 A CN201780046065 A CN 201780046065A CN 109562179 A CN109562179 A CN 109562179A
Authority
CN
China
Prior art keywords
pharmaceutically acceptable
paracetamol
bis
derivative
mercaptoethyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201780046065.1A
Other languages
English (en)
Chinese (zh)
Inventor
博伊德·尤金·哈利
雷格纳·阿克塞尔·西奥多·克林伯格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EmeraMed Ltd
Original Assignee
Ermes Medical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ermes Medical Co Ltd filed Critical Ermes Medical Co Ltd
Publication of CN109562179A publication Critical patent/CN109562179A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CN201780046065.1A 2016-08-05 2017-08-04 N,n-双-2-巯基乙基间苯二甲酰胺的新用途 Pending CN109562179A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1613535.2 2016-08-05
GB201613535 2016-08-05
PCT/GB2017/052306 WO2018025049A1 (en) 2016-08-05 2017-08-04 New use of n,n-bis-2-mercaptoethyl isophthalamide

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CN202511855908.5A Division CN121926911A (zh) 2016-08-05 2017-08-04 N,n-双-2-巯基乙基间苯二甲酰胺的新用途

Publications (1)

Publication Number Publication Date
CN109562179A true CN109562179A (zh) 2019-04-02

Family

ID=60202272

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201780046065.1A Pending CN109562179A (zh) 2016-08-05 2017-08-04 N,n-双-2-巯基乙基间苯二甲酰胺的新用途

Country Status (30)

Country Link
US (2) US20190240173A1 (https=)
EP (2) EP4029497A1 (https=)
JP (1) JP6926192B2 (https=)
KR (1) KR102538388B1 (https=)
CN (1) CN109562179A (https=)
AU (1) AU2017305661B2 (https=)
BR (1) BR112019002130A2 (https=)
CL (1) CL2019000229A1 (https=)
CY (1) CY1125039T1 (https=)
DK (1) DK3493849T3 (https=)
EA (1) EA201990443A1 (https=)
ES (1) ES2907838T3 (https=)
HR (1) HRP20220252T1 (https=)
HU (1) HUE057782T2 (https=)
IL (1) IL264538B2 (https=)
LT (1) LT3493849T (https=)
MA (1) MA45855B1 (https=)
MD (1) MD3493849T2 (https=)
MX (1) MX387853B (https=)
MY (1) MY199733A (https=)
PH (1) PH12019500237A1 (https=)
PL (1) PL3493849T3 (https=)
PT (1) PT3493849T (https=)
RS (1) RS62924B1 (https=)
SG (1) SG11201900565RA (https=)
SI (1) SI3493849T1 (https=)
SM (1) SMT202200109T1 (https=)
UA (1) UA125394C2 (https=)
WO (1) WO2018025049A1 (https=)
ZA (1) ZA201900594B (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB202005057D0 (en) 2020-04-06 2020-05-20 Emeramed Ltd New Use
WO2026037909A1 (en) * 2024-08-16 2026-02-19 Emeramed Limited N,n-bis-2-mercaptoethyl isophthalamide for use in the treatment of pain

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100227812A1 (en) * 2008-12-06 2010-09-09 Haley Boyd E Method of supplementing the diet and ameliorating oxidative stress

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6586600B2 (en) 2000-12-06 2003-07-01 University Of Kentucky Research Foundation Multidentate sulfur-containing ligands
US20120122787A1 (en) 2009-07-10 2012-05-17 Rong Li Methods for treating polycystic kidney disease (pkd) or other cyst forming diseases
JP2013505963A (ja) 2009-09-28 2013-02-21 ユニヴァーシティ オブ ケンタッキー リサーチ ファウンデイション 汚染された環境から元素を除去するチオール含有化合物およびその使用方法
US8575218B2 (en) 2009-09-28 2013-11-05 The University Of Kentucky Research Foundation Thiol-containing compounds for the removal of elements from tissues and formulations therefor
US20110237776A1 (en) 2010-03-25 2011-09-29 Haley Boyd E Aromatic compounds with sulfur containing ligands
US8426368B2 (en) 2010-03-25 2013-04-23 The University Of Kentucky Research Foundation Method of ameliorating oxidative stress and supplementing the diet

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100227812A1 (en) * 2008-12-06 2010-09-09 Haley Boyd E Method of supplementing the diet and ameliorating oxidative stress

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
王德仙: "氢生理盐水对对乙酰氨基酚所致小鼠肝损伤的保护作用", 《中国优秀硕士学位论文全文数据库医药卫生辑》 *

Also Published As

Publication number Publication date
MA45855B1 (fr) 2022-02-28
PT3493849T (pt) 2022-02-23
MY199733A (en) 2023-11-21
PL3493849T3 (pl) 2022-03-28
AU2017305661A1 (en) 2019-02-14
AU2017305661B2 (en) 2023-05-18
IL264538B (en) 2022-10-01
IL264538A (https=) 2019-03-31
JP2019524782A (ja) 2019-09-05
SI3493849T1 (sl) 2022-04-29
KR20190035724A (ko) 2019-04-03
EP4029497A1 (en) 2022-07-20
BR112019002130A2 (pt) 2019-05-14
JP6926192B2 (ja) 2021-08-25
CL2019000229A1 (es) 2019-04-26
CY1125039T1 (el) 2023-03-24
CA3032858A1 (en) 2018-02-08
MD3493849T2 (ro) 2022-04-30
EP3493849A1 (en) 2019-06-12
MX387853B (es) 2025-03-19
PH12019500237A1 (en) 2019-10-28
NZ750271A (en) 2025-07-25
ZA201900594B (en) 2019-08-28
MX2019000978A (es) 2019-06-10
WO2018025049A1 (en) 2018-02-08
LT3493849T (lt) 2022-03-10
EP3493849B1 (en) 2021-12-01
DK3493849T3 (en) 2022-03-07
HUE057782T2 (hu) 2022-06-28
KR102538388B1 (ko) 2023-05-30
MA45855A (fr) 2021-03-17
HRP20220252T1 (hr) 2022-04-29
UA125394C2 (uk) 2022-03-02
ES2907838T3 (es) 2022-04-26
US20250325503A1 (en) 2025-10-23
US20190240173A1 (en) 2019-08-08
SMT202200109T1 (it) 2022-05-12
SG11201900565RA (en) 2019-02-27
EA201990443A1 (ru) 2019-07-31
RS62924B1 (sr) 2022-03-31
IL264538B2 (en) 2023-02-01

Similar Documents

Publication Publication Date Title
BR112020012586A2 (pt) composições e métodos de tratamento para transtornos neurológicos que contenham uma forma de demência
BRPI0912607A2 (pt) medicamento consistindo em uso concomitante ou combinação de inibidor de dpp-iv e outro medicamento para o diabete
KR20230009425A (ko) 신경보호에서의 글루타티온 트리술피드 (gsssg)
CN101278928A (zh) 含左卡尼汀或其衍生物的药物组合物及其用途
US20250325503A1 (en) New use of n,n-bis-2-mercaptoethyl isophthalamide
RU2010129825A (ru) Материалы и способы для лечения патологической пролиферации глазных сосудов
BR112020008128A2 (pt) comprimidos de liberação retardada de deferiprona e métodos para utilização dos mesmos
BR112020014719A2 (pt) Tratamento de hipoglicemia pós-bariátrica usando glucagon estável em minidose
JP2025072496A (ja) ジスキネジア治療薬
EP1463440B1 (en) Prevention of flap necrosis in plastic surgery
CN109417016A (zh) 用于治疗缺血-再灌注损伤的戊二酸化合物
JPS61106521A (ja) 血管増殖抑制剤
PT97563A (pt) Processo para a preparacao de uma composicao farmaceutica contendo misoprostol e um agente analgesico, por exemplo diclofenac, e metodo para o tratamento da dor utilizando a referida composicao
CN101744806B (zh) 松属素外消旋体在制备治疗脑卒中药物中的用途
JP2024016228A (ja) アセトアミノフェン（ａｐａｐ）によって引き起こされる毒性を予防、低減または根絶するための方法および組成物
TWI257864B (en) Therapeutic or preventive agent for liver diseases containing a diaminotrifluoromethylpyridine derivative
EA029157B1 (ru) Терапия макулярной дегенерации на основе баклофена и акампросата
KR101008052B1 (ko) 경피흡수형 뇌 보호제
Hodgson et al. Acute arsenic exposure secondary to deliberate self-poisoning with sheep dip
Francisco et al. Therapeutic plasma exchange for apixaban removal in the setting of delayed clearance and life-threatening bleeding
Zhong et al. Positive inotropic drugs and drugs used in dysrhythmias
CA3032858C (en) Use of n,n-bis-2-mercaptoethyl isophthalamide to prevent or treat paracetamol toxicity
CN121926911A (zh) N,n-双-2-巯基乙基间苯二甲酰胺的新用途
HK40005150B (en) New use of n,n-bis-2-mercaptoethyl isophthalamide
EP4525864A2 (en) Compounds and pharmaceutical compositions useful for managing sickle cell disease and conditions related thereto

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination